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Abstract
Background: Adverse reactions induced by BCG vaccination are rare, disseminated
mycobacterial BCG infection in particular, which is often fatal and results from impaired immunity.
The aim of this study is to determine the nature of the immunodeficiences in patients with
disseminated BCG infection in northwest region of Iran.
Materials and methods: Through 2 years all infants with BCG adenitis or other complications
of this vaccine that had suspicious BCG infection were referred to children's hospital and health
centers of Tabriz.
Evaluation of immune system and in some cases genetic survey was performed in infants with
evidence of histopathologic demonstration of acid-fast bacilli. Then frequency of infants who had
disseminated BCG infection with immunodeficiency was defined.
Results: From 48 selected infants with complications of BCG vaccine in the range of 2 to 62
months, 28 infants (58.3%) were male and 20 infants (41.7%) were female. Disseminated BCG
infection was diagnosed in 11 cases, almost all of whom had immunodeficiency as follows:
Seven cases had severe combined immunodeficiency and one cases had chronic granulomatous
disease. MSMD in two cases and IL12 R deficiency in another one was diagnosed.
Overall, the mortality rate was 72.8% (8 cases) which 7 cases of them were SCID and another one
CGD
Consanguineous was found in more than half (7 cases) of patients and family history of disseminated
BCG infection or immunodeficiency was found in nearly one third (3 cases) of patients.
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Discussion: BCG vaccine is administered world wide to prevent tuberculosis and is considered
to have excellent safety profile. However in some immunodeficient patients it can cause severe and
fatal complications, like in our region, where all cases of disseminated BCG infection with severe
immunodeficiency died.
Conclusion: BCG vaccination is necessary in some countries such as Iran, so it seems that
development of a more safer vaccine and change of vaccine program in the families with history of
inherited immunodeficiency can be identifies such high risk infants and prophylaxis of severe
complications or dead in such patients.
Introduction
In Iran BCG sub strain Pasteur vaccine, is administered to
all the newborns at birth to prevent tuberculosis. Adverse
reactions induced by BCG vaccination are rare (ranging
from zero to 23.8%) [1,2]. The most frequent complica-
tions are purulent regional lymphadenitis (0.9 per 1000
vaccinated children) [2]. Bone BCG infection is the sec-
ond most frequent (0.39 to 46 per million vaccinated chil-
dren) [3-5]. Disseminated infections are even rarer and
their estimated incidence is 0.1 to 4.3 per one million vac-
cinated children but is lethal in 50 to 71% of the cases [6-
8]. The death rate is especially higher in cases of immun-
odepression (83%) and it is important that a temporary or
permanent immune deficiency observed in 86% of the
cases [6-9]. Disseminated BCG infections have occurred
in children with immunodeficiency disorders such as
severe combined immunodeficiency (SCID), chronic
granulomatous disease (CGD), complete Di George syn-
drome, AIDS and idiopathic immunodeficiency of genetic
origin or mendelian susceptibility to mycobacterial dis-
ease(MSMD) with underlying genetic defects, but only
rarely in apparently normal individuals[6,8-10].
The aim of this study was to determine the role of immu-
nodeficiency disorders in exciting disseminated BCG
infection.
Materials and methods
This prospective study was performed through 24- month
period by TB and lung disease research center of Tabriz
because of in Iran all children at birth immunize with
BCG vaccine. So, Children with BCG lymphadenitis and
criteria as follows were referred to children's hospital from
health centers by convenience sampling.
Inclusion criteria were: Lymphadenitis, Abscesses or fis-
tula in the site of BCG vaccination or another site or BCG
ulceration with 2 or more than of following such as:
1. Fever >38°c more than 2 weeks
2. Anemia (Hb<10)
3. Recurrent or persistent oral Candida
4. Organomegaly (Hepatosplenomegaly)
5. Bone diseases (Pain or arthritis)
6. Weight loss
7. Recurrent or persistent diarrhea
8. Related parents
9. Family history of immunodeficiency
Then physical examination and laboratory studies were
performed based on:
1. A systemic syndrome compatible with mycobacte-
rial disease. Typical manifestations include fever,
weight loss, anemia and death.
2. Evidence of infection by positive acid-fast bacilli on
smears and growth of M. bovis, BCG strain at two or
more anatomic sites beyond the region of vaccination.
The competency of the immune system were evaluated by
different tests including measurement of Igs, Isohema-
glotination test, phagocyte activity by NBT (slide test), T
and B cell counts by flowcytometry, delayed type hyper-
sensitivity test (DHT). HIV performed by Elisa test. These
tests were performed by standard procedures and by
trained laboratory personnel in the specialized laborato-
ries.
Clinical manifestations and hematological and immuno-
logic changes were compared between two different
groups of cases: Patients (who are children with dissemi-
nated BCG infection) and control group (who are chil-
dren with complications of BCG vaccination but without
disseminated BCG infection). Then frequency of patients
with disseminated BCG infection who had immunodefi-
ciency was reported.
The children and their parents were informed about the
necessary clinical and laboratory examination procedures
and their consent was taken before the start of the study.
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Static
Sings, symptoms and laboratory findings were compared
between patients and control by Chi-square test and fisher
exact test. Also, we used student t-test for comparation
between T, B, NK cells and SPSS 14 for data analysis.
Results
In this survey from 122093 BCG vaccinated children
through 24 month period,48 infants with BCG lymphad-
enitis, within range of 2-62 months (mean ± SD: 9.9 ±
9.85) were selected. 28 infants were male (58.3%) and 20
infants were female (41.7%).
Onset age was between 1-21 months (mean ± SD: 6.36 ±
4.62). Twenty four cases had multiple lymphadenitis near
to BCG incubation such as cervical, axiliary, and supracla-
viculs, 11 cases had suppurative lymphadenitis with fis-
tula and abscesses and 5 cases had ulcer of BCG
incubation. Osteomyelitis due to BCG vaccination was
detected in 2 cases and disseminated BCG infection in 11
cases (22.9%) with multi organ involvement and systemic
symptoms was detected. Family history of BCG infection
or immunodeficiency was positive in 22.9% of control
group and the rate of consanguineous marriages in the
parents of them was 37.5% (18 cases).
A chi-square test comparing the clinical manifestations in
children with disseminated BCG infection with control
group showed statistically significant differences for the
two groups of children (Table 1).
Definitive immunodeficiency was detected in approxi-
mately all of children with disseminated BCG infection
including: SCID in 7 cases with homozygous mutation
and homozygous polymorphism in Rag2 in one patient
with heterozygous for the Rag2 mutation and polymor-
phism in the both parents of him and exclusion of Rag1,
Rag2 and Artemis defect in another patients.
Other cases were CGD, IL12RB1 deficiency and MSMD. In
one cases of MSMD we could exclude an IL12RB1 defi-
ciency. So he had a normal expression of IL12RB1on cell
surface with two different antibodies. HIV was not identi-
fied in any of the cases (Table 2).
Comparison of immunologic markers showed that signif-
icant differences were seen between two groups of chil-
dren. The mean value of CD3 in patients was (P = 0.005)
in comparison with control group and the mean value of
CD4 in patients was (P < 0.001) in comparison with con-
trol group (Table 3).
Although antimycobacterial regimens used for the treat-
ment of patients with 4 drugs, but 8 of the patients died
despite aggressive management.
Discussion
BCG is a live attenuated bacterial vaccine that protects
children from miliary tuberculosis and tuberculosis men-
ingitis [10]. It is considered a safe vaccine with a low inci-
dence of complications, such as purulent lymphadenitis
and Bone BCG infection [2,3,9,11,12]. A disseminated
infection is even rarer [6-8] but in recent years has
increased up 0-1/100000 vaccinated children [6-8,13].
Lotte et al identified 60 cases of dissemination for which
the mortality rate was %50 and cellular immunodefi-
ciency was identified as the chief risk factors for fatal out-
come [14,15]. Additionally the estimated incidence of
disseminated disease in the 5.5 million vaccinated infants
in six European countries was 2 cases per 1 million vacci-
nated children, and the mortality rate was 80% [14]. Dis-
seminated BCG infections have occurred following
vaccination of children with immunodeficiency disorders
but only rarely in apparently normal individuals [6,8-
10,16-20].
Also in 28 cases of definite disseminated BCG disease in
13 countries; immune defects were identified in 24(86%)
Table 1: Comparison of clinical and laboratory findings in patients and control groups
Clinical and laboratory findings Patient Number (%) Control Number (%) P. value
Lymphadenopathy 5(45) 10(27) 0.28
Organomegaly 5(45) 0 <0.001
Bone involvement 3(27.3) 1(2.7) 0.033
Lung involvement 9(81.8) 3(8.1) <0.001
Thymus atrophy 9(81.8) 0 <0.001
Recurrent diarrhea 8(72.7) 9(24.3) 0.009
Recurrent infection 8(72.7) 3(8.1) <0.001
Oral Candida 9(81.8) 5(13.5) <0.001
Fever 11(100) 15(41.7) 0.005
Lymphopenia 8(72.7) 3(8.1) <0.001
Anemia 11(100) 19(51.4) 0.003
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of cases. Of 20 patients who died of disseminated BCG
disease, all had an immune defect whereas the mortality
rate among patients without an identified immunodefi-
ciency was zero [6]. In Canada, 21 BCG vaccinated child
with adverse reactions have detected with 6 disseminated
BCG infection which 5 of them were died [21].
In our study 2/3 of our patients with disseminated BCG
infection, had immunodeficiency that all of them died.
Our results are compatible with our pilot study that was
done in children's hospital of Tabriz. In this study we
could identify 8 cases of immunodeficiency that all of
them had severe combined immunodeficiency and died
due to disseminated BCG infection with mortality
rate100% (in press). Also in retrospective study of 17
cases with disseminated BCG in Tehran impaired immu-
nity was detected in 10 cases that all of them died [22].
Complications of BCG vaccine usually develops 5 months
to 5 years after vaccination [6,9,22]. Also review over 5000
reports showed that 71%(20) of 28 cases occurred in
patients younger than 2 years of age [6]. In our study,
except 2 cases that were within 3 years old, all of them
were younger than one year old.
The most commonly reported symptoms in the definite
cases of disseminated BCG disease were fever, diarrhea,
cough, Lymphadenopathy and weight loss, FTT and
Hepatosplenomegaly, were also common
[6,15,19,22,23]. In our study fever was in 100% and oral
Candida was in 81.8%. Also thymus atrophy in 81.8% of
patients was found. Anemia was the most common sign
in our patients which was found in 100% of patients.
On the other hands, more than half (7 of 11 cases) of our
patients had related parents which is compatible with
study of Casanova et al. that parental consanguinity was
found in 30% of the families [8] and also in study by
Afshar et al. that related parents was found in 82/35% of
patients [22].
Conclusion
AT present BCG inoculation is necessary in countries with
high incidence of tuberculosis, but has a high mortality in
patients with primary immunodeficiency, so it seems to
make an effort in development of a more safer, inoffen-
sive vaccine with minimum side effects are a necessity
because infants with immunodeficiency are vaccinated at
birth prior to diagnosis.
Table 2: summary of data on children with disseminated BCG infection
Number Age/sex Site(s) of dissemination Immune defect Outcome Consanguinity Family history 
immunodeficiency
1 9 mo/M Chest, Spleen MSMD Survived -
2 3year/M As cite, CNS Bone CGD died -
3 4 mo/M DLN, Liver SCID Rag2 deficiency
T-B-NK+
died + +
4 4 mo/M Bone, Pericardia Liver Omen syn
T+B-NK+
died +
5 6 mo/F Gastric aspirate, DLN T-B-NK+
SCID
died -
6 5 mo/F DLN, Liver T-B-NK+
SCID
died + +
7 4/5 mo/M Eye, DLN, Lung (Miliary) *T-B-NK+
SCID
died +
8 5 mo/F As cite, Liver, DLN SCID
T-B+NK+
died +
9 3.5 years/M Bone, Skin, DLN MSMD Survived - +
10 4 mo/F DLN, Gastric aspiration IL12 R
deficiency
Survived +
11 4 mo/F Urine, Liver SCID
T-B+NK+
died +
* Exclusion of Rag1, Rag2 and Artemis defect
CMID = cell mediated immune defect, CGD = chronic granulomatous disease, SCID = severe combined immunodeficiency, DLN = distal lymph 
node.
Table 3: The mean of immunologic markers in patients and 
control groups





CD3 30.82 ± 28.98 62.11 ± 8.77 0.005
CD4 13.36 ± 14.21 42.12 ± 11.34 0.001
CD8 19.00 ± 13.61 22.30 ± 6.06 0.452
CD19 23.91 ± 15.40 21.19 ± 8.26 0.586
CD56 35.18 ± 30.46 10.57 ± 4.90 0.029
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On the other hands, inoculation of BCG vaccine should
be prohibited for a few months in the families with his-
tory of inherited immunodeficiency. Also, screening of
newborns at birth for SCID especially in region with high
incidence of SCID such as in the North West Iran [24] can
be useful for identify high risk children.
Finally BCG lymphadenitis with concomitant signs and
symptoms that we mentioned in our study, are requisite
for evaluation of underlying disorders such as immunode-
ficiency.
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